Zhu Bo, Chan Siu-Lung, Li Jack, Li Kathryn, Wu Hao, Cui Kui, Chen Hong
Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States.
Front Cardiovasc Med. 2021 Sep 7;8:742382. doi: 10.3389/fcvm.2021.742382. eCollection 2021.
There has been a rise in the prevalence of non-alcohol fatty liver disease (NAFLD) due to the popularity of western diets and sedentary lifestyles. One quarter of NAFLD patients is diagnosed with non-alcoholic steatohepatitis (NASH), with histological evidence not only of fat accumulation in hepatocytes but also of liver cell injury and death due to long-term inflammation. Severe NASH patients have increased risks of cirrhosis and liver cancer. In this review, we discuss the pathogenesis and current methods of diagnosis for NASH, and current status of drug development for this life-threatening liver disease.
由于西方饮食的流行和久坐不动的生活方式，非酒精性脂肪性肝病（NAFLD）的患病率有所上升。四分之一的NAFLD患者被诊断为非酒精性脂肪性肝炎（NASH），其组织学证据不仅包括肝细胞中的脂肪堆积，还包括长期炎症导致的肝细胞损伤和死亡。严重的NASH患者患肝硬化和肝癌的风险增加。在这篇综述中，我们讨论了NASH的发病机制、当前的诊断方法以及这种危及生命的肝脏疾病的药物研发现状。
